现代医药卫生2025，Vol.41Issue(9)：2023-2028,6.DOI:10.3969/j.issn.1009-5519.2025.09.002
2025版《原发性醛固酮增多症:内分泌学会临床实践指南》解读
Interpretation of 2025 edition of Primary Aldosteronism:Clinical Practice Guidelines of the Endocrine Society
摘要
Abstract
Primary aldosteronism(PA)is a common secondary hypertension caused by excessive au-tonomous secretion of aldosterone due to adrenal cortical lesions.It is often misdiagnosed or missed.In 2025,the American College of Clinical Endocrinology,in collaboration with the American Heart Association,the Eu-ropean Endocrine Society,the European Society of Hypertension,and other international authoritative institu-tions,jointly released the new"Primary Aldosteronism:Clinical Practice Guidelines of the Endocrine Society"(hereinafter referred to as"the New Guideline").This is the first optimization and update of the PA diagnosis and treatment guidelines by the American College of Clinical Endocrinology in 9 years,and undoubtedly will have a significant impact on the clinical diagnosis and treatment of PA.The New Guideline have focused on optimizing key aspects such as screening,diagnosis,classification,and treatment of PA,and widely cited the latest evidence-based medical evidence.It is worth noting that the New Guideline cited 25 research results from China,including 8 from the CONPASS team of the First Affiliated Hospital of Chongqing Medical Uni-versity,5 from Taiwan,China,and 3 from the affiliated hospital of Central South University.This highlights the increasingly significant international influence of Chinese scholars in the field of PA research.关键词
原发性醛固酮增多症/临床实践/高血压/指南解读Key words
Primary aldosteronism/Clinical practice/Hypertension/Guideline interpretation分类
医药卫生引用本文复制引用
申航,胡金波,杨淑敏,李启富..2025版《原发性醛固酮增多症:内分泌学会临床实践指南》解读[J].现代医药卫生,2025,41(9):2023-2028,6.基金项目
重庆市科卫联合医学科研项目"医学科技创新攻关工程"(2025GGXM004) （2025GGXM004）
重庆市技术创新与应用发展专项重点项目(CSTB2024TIAD-KPX0039). （CSTB2024TIAD-KPX0039）
